subscribeSubscribe
Darolutamide Phase III ARANOTE Trial Meets Primary Endpoint

Darolutamide Phase III ARANOTE Trial Meets Primary Endpoint
GLOBENEWSWIRE
17 Jul 2024
Share Share
Bayer eyes wider Nubeqa use on new prostate cancer trial data

Bayer eyes wider Nubeqa use on new prostate cancer trial data
Ludwig Burger REUTERS
17 Jul 2024
Share Share
Darolutamide: A Promising Advancement in Prostate Cancer Treatment

Darolutamide: A Promising Advancement in Prostate Cancer Treatment
PRESS RELEASE
07 Jun 2024
Share Share
Bayer reports drop in Q1 sales amidst patent litigation challenges

Bayer reports drop in Q1 sales amidst patent litigation challenges
Akosua Mireku PHARMACEUTICAL TECHNOLOGY
14 May 2024
Share Share
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
GLOBENEWSWIRE
27 Mar 2024
Share Share
Bayer Pharmaceuticals advances next generation of blockbuster medicines

Bayer Pharmaceuticals advances next generation of blockbuster medicines
PRESS RELEASE
21 Mar 2024
Share Share
FDA Confirms Paragraph IV Patent Litigation for Darolutamide Tablets

FDA Confirms Paragraph IV Patent Litigation for Darolutamide Tablets
FDA
08 Sep 2023
Share Share
Celcuity Enters into Collaboration with Bayer to Provide Nubeqa

Celcuity Enters into Collaboration with Bayer to Provide Nubeqa
GLOBENEWSWIRE
22 Aug 2023
Share Share
Bayer`s Nubeqa, AZ`s Forxiga pick up nods from UK`s NICE

Bayer`s Nubeqa, AZ`s Forxiga pick up nods from UK`s NICE
Zoey Becker FIERCE PHARMA
22 May 2023
Share Share
Bayer`s potential blockbusters Nubeqa, Kerendia thrive in Q1

Bayer`s potential blockbusters Nubeqa, Kerendia thrive in Q1
Kevin Dunleavy FIERCE PHARMA
11 May 2023
Share Share